SER Serina Therapeutics Inc.
Price (delayed)
$6.18
Market cap
$54.89M
P/E Ratio
1.2
Dividend/share
N/A
EPS
$5.16
Enterprise value
$60.48M
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic
Highlights
The net income has surged by 170% since the previous quarter and by 37% year-on-year
The P/E is 77% lower than the last 4 quarters average of 5.6
The company's debt has shrunk by 65% YoY but it rose by 6% QoQ
The quick ratio has declined by 22% since the previous quarter
Key stats
What are the main financial stats of SER
Market
Valuations
Earnings
Shares outstanding
8.88M
Market cap
$54.89M
Enterprise value
$60.48M
Price to earnings (P/E)
1.2
Price to book (P/B)
N/A
Price to sales (P/S)
16.49
EV/EBIT
10.1
EV/EBITDA
9.47
EV/Sales
18.96
Revenue
$3.19M
EBIT
$5.99M
EBITDA
$6.39M
Free cash flow
-$8.7M
Per share
Balance sheet
Liquidity
EPS
$5.16
Free cash flow per share
-$1.02
Book value per share
-$1.94
Revenue per share
$0.37
TBVPS
$1.19
Total assets
$10.71M
Total liabilities
$27.1M
Debt
$11.71M
Equity
-$16.36M
Working capital
-$3.72M
Debt to equity
-0.72
Current ratio
0.71
Quick ratio
0.49
Net debt/EBITDA
0.88
Margins
Efficiency
Dividend
EBITDA margin
200.1%
Gross margin
100.2%
Net margin
218.9%
Operating margin
-165.4%
Return on assets
65.3%
Return on equity
N/A
Return on invested capital
155.1%
Return on capital employed
N/A
Return on sales
187.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SER stock price
How has the Serina Therapeutics stock price performed over time
Intraday
-8.44%
1 week
-22.46%
1 month
-3.74%
1 year
-74.16%
YTD
-54.36%
QTD
-35.49%
Financial performance
How have Serina Therapeutics's revenue and profit performed over time
Revenue
$3.19M
Gross profit
$3.2M
Operating income
-$5.28M
Net income
$6.98M
Gross margin
100.2%
Net margin
218.9%
The net income has surged by 170% since the previous quarter and by 37% year-on-year
The company's net margin has surged by 166% QoQ but it has shrunk by 74% YoY
The company's operating income has shrunk by 124% QoQ
The company's operating margin has shrunk by 121% QoQ and by 87% YoY
Growth
What is Serina Therapeutics's growth rate over time
Valuation
What is Serina Therapeutics stock price valuation
P/E
1.2
P/B
N/A
P/S
16.49
EV/EBIT
10.1
EV/EBITDA
9.47
EV/Sales
18.96
The P/E is 77% lower than the last 4 quarters average of 5.6
The company's EPS rose by 7% YoY and by 4.9% QoQ
The equity is up by 26% year-on-year
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 127.7 and 16% lower than the last 4 quarters average of 21.5
Efficiency
How efficient is Serina Therapeutics business performance
Serina Therapeutics's ROA has soared by 179% from the previous quarter but it has decreased by 12% YoY
The company's return on sales has shrunk by 70% YoY
Dividends
What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SER.
Financial health
How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 60% lower than its total liabilities
The company's total liabilities has surged by 79% QoQ but it fell by 22% YoY
The quick ratio has declined by 22% since the previous quarter
The company's debt is 172% higher than its equity
The debt to equity has surged by 72% since the previous quarter and by 52% year-on-year
The company's debt has shrunk by 65% YoY but it rose by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.